Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02685176
Other study ID # B2015:101
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2016
Est. completion date September 30, 2018

Study information

Verified date March 2018
Source University of Manitoba
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This Clinical trial is being conducted to study the effectiveness of heat donation through head or torso in hypothermic rewarming efficacy using a human model for severe hypothermia. The purpose of the study is to compare the core rewarming effectiveness of the same amount of heat donation through the head or torso in treatment of hypothermia using a human model for severe hypothermia. The information obtained from this study will give a better understanding of heat-transfer mechanisms. This might help in the ongoing research in hypothermia treatment.


Description:

Procedure:

Eight healthy, non-pregnant participants between 18 and 45 years old will be cooled in 8°C water, for 60 minutes or to a core temperature of 35ºC on three occasions and then warmed by each of three warming conditions.

The study will include following specific procedures:

Anthropometric data which includes age, weight, height, and measurements of skinfold thickness at four sites- biceps, triceps, subscapularis, and suprailiac will be collected. Participant's heart rate and electrocardiogram will be monitored continuously throughout the experiment.

Conditions: The three treatment methods are as follows. A. Spontaneous rewarming (Shivering inhibition) In this control condition, Demerol will be infused through the arm or hand vein.

The first 1.5 mg/kg will be slowly injected in five equal doses (of 0.3 mg/kg) at 2 minute intervals during the last 10 minutes of cold water immersion. After removal from the water, further aliquots of 0.3 mg/kg (at minimum of 2-minute intervals) will be given only as necessary to inhibit any shivering that may develop, to a maximum cumulative dose of 3.2 mg/kg body weight.

After towel drying the subject will lie on a mattress under an insulated cover without any extra heating modality. Spontaneous rewarming will be the first condition for every subject, the results will be used to determine the dosage schedule for demerol in the active warming conditions below.

B. Head warming:

Charcoal Heater applied to the Head (CH-H) - A charcoal heater (HEATPAC Personal Heater, Emergco Tech. Solutions, Vancouver) consists of a combustion chamber, a canister containing the charcoal fuel, and a branched heating duct that produces 250 W of heat. The canister is placed inside the combustion chamber and the charcoal fuel is ignited. Heated air is blown through the impermeable heating ducts by a fan within the charcoal heater above the combustion chamber. The combustion chamber will be placed on right side of the face/head with ducts wrapping around the dorsum of the head, anteriorly over the forehead, nose, chin and the neck, not covering the eyes or the mouth. The participant will be breathing ambient air (̴ 22˚C).

C. Torso warming:

Charcoal Heater to the Torso (CH-T) - The same charcoal heater as above will be used. The combustion chamber will be placed on the subject's anterior chest with a towel in between. The flexible ducts will be applied to the areas of high heat transfer i.e. over the shoulders, neck, and then anteriorly under the axillae to cross over the lower anterior chest. Participant will be breathing ambient air at room temperature (~22˚C).

Rewarming procedures will be administered either for a period of 60 minutes or until core temperature returns to normal values ( ̴ 36.5-37˚C). Following that, participants will be placed in a warm water bath (40-42˚C) until they wish to exit or core temperature reaches 37°C.

Research Design:

Each of the three experimental trials will be separated by at least 48 hours. On each of the three trials, participants will be immersed up to the level of the sternal notch in 8˚C for up to 60 minutes or until the core temperature falls to 35˚C. Demerol will be administered by a licensed physician during the final 10 minutes of immersion to suppress shivering. Participants will then exit the water, be dried off and rewarmed with either head or torso warming techniques. After removal from the water, an extra dosage of demerol might be given to suppress shivering only if its necessary. The rewarming will be administered for 120 minutes or until the core temperature returns to normal values (̴36.5-37˚C). The order of warming methods will follow a modified balanced design with control being first and the two active warming conditions being balanced.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date September 30, 2018
Est. primary completion date September 30, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Healthy adults, who answer "No" to all the questions on a Physical Activity Readiness Questionnaire (PAR-Q). Participants will also be interviewed to determine if they have any cardio-respiratory diseases, Raynaud's Syndrome, or any other conditions that can be aggravated by cold exposure.

Exclusion Criteria:

- A positive answer to any PAR-Q question, or any cardio-respiratory diseases, Renal dysfunction, Raynaud's Syndrome, past recreational drug use or any other conditions that can be aggravated by cold exposure.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Charcoal Heater (STK Heatpac, Emergco Tech Solutions, B.C.)
A heater (STK Heatpac) will be used in the active warming arms of the study.
Other:
No heat
No active heating provided post cooling

Locations

Country Name City State
Canada University of Manitoba Winnipeg Manitoba

Sponsors (1)

Lead Sponsor Collaborator
University of Manitoba

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rewarming Rate Rate of core temperature increase during rewarming 120 minutes
See also
  Status Clinical Trial Phase
Completed NCT05669313 - The Effects of Hypothermia and Acidosis on Coagulation During Treatment With Rivaroxaban Measured With ROTEM
Not yet recruiting NCT05306392 - Effects of Induced Moderate Hypothermia on ARDS Patients Under Venovenous ExtraCorporeal Membrane Oxygenation N/A
Withdrawn NCT02812069 - WarmSmart Warming Protocol N/A
Completed NCT02586974 - Effects of Warmed, Humidified CO2 Insufflation on Body Core Temperature and Cytokine Response N/A
Not yet recruiting NCT02211703 - National Epidemiologic Survey on the Incidence of Perioperative Hypothermia N/A
Completed NCT02177903 - Study to Determine the Effects of Pre-warming on OR Patient Temperatures and Surgical Outcomes N/A
Completed NCT02742818 - Forced-air Warming in Endovascular Surgery: Testing Effectiveness of Two Different Blanket Models N/A
Completed NCT02121574 - Accuracy of Zero-flux and Ingestible Thermometers N/A
Recruiting NCT01866384 - Targeted Temperature Management After Intracerebral Hemorrhage Phase 2
Active, not recruiting NCT01529658 - Renal Hypothermia During Partial Nephrectomy N/A
Completed NCT01722955 - Pre-warmed Intravenous Fluids and Monitored Anesthesia Care N/A
Completed NCT01793337 - Core Body Temperature Measurement During Hot and Cold Environmental Exposure N/A
Completed NCT01559675 - Trial Comparing Low Dose and High Dose Steroids in Patients Undergoing Colorectal Surgery N/A
Terminated NCT01018576 - Delayed Cord Clamping in Premature Infants N/A
Terminated NCT00822796 - Thermogard™ Efficacy Trial N/A
Completed NCT00904228 - Plastic Hat Trial to Prevent Hypothermia in Preterm Newborns in the Delivery Room N/A
Completed NCT00334360 - Dexmed/Buspirone Synergism on Shivering Phase 4
Not yet recruiting NCT06283771 - The Effect of Heated Socks Developed With Wearable Technology on Hypothermia, Thermal Comfort Perception and Shivering N/A
Completed NCT04399902 - Study to Actively Warm Trauma Patients N/A
Completed NCT03450668 - mOm Incubator Pilot Study N/A